People | May 01, 2026
Microbot Medical Inc. appoints Alon Tamir as VP Sales EMEA
Tamir brings more than 20 years of experience in the medical technology sector
Tamir brings more than 20 years of experience in the medical technology sector
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
Health innovations are viewed more positively than food and agricultural technologies
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
New acetabular system enhances precision, stability and robotic compatibility in total hip arthroplasty
The submission is backed by positive results from the Phase 3 AFFIRM study
Subscribe To Our Newsletter & Stay Updated
